General Discussions

FDA Approves Eribulin for Metastatic Liposarcoma

By Silas Inman
General Discussions - Discussions
1 replies
Richard Pazdur, MD

Richard Pazdur, MD

The FDA has approved eribulin mesylate (Halaven) to treat patients with advanced or unresectable liposarcoma following prior treatment with an anthracycline-based chemotherapy. Eribulin mesylate marks the first drug to be approved for liposarcoma that showed an overall survival benefit for patients.

In a subpopulation of 143 patients in study with liposarcoma, the microtubule dynamics inhibitor eribulin demonstrated a median overall survival (OS) of 15.6 months compared with 8.4 months in those who received dacarbazine (HR, 0.51; 95% CI, 0.35-0.75).

“Halaven is the first drug approved for patients with liposarcoma that has demonstrated an improvement in survival time,” Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in a statement. “The clinical trial data the FDA reviewed indicates that Halaven increased overall survival by approximately seven months, offering patients a clinically meaningful drug.”

Findings from the open-label phase III trial were presented at the 2015 ASCO Annual Meeting. Under the Prescription Drug User Fee Act, the FDA was scheduled to make a decision on the application by March 30, 2016, placing their decision approximately 2 months ahead of deadline.

In the pivotal phase III study, 452 patients with advanced soft tissue sarcoma were randomized to receive eribulin (n = 228) or dacarbazine (n = 224). Eribulin was administered at 1.4 mg/m2 on days 1 and 8 and dacarbazine was administered at 850, 1000, or 1200 mg/m2 on day 1 of each 21-day cycle.

Patients enrolled had high- or intermediate-grade sarcoma and the majority had received 2 or more prior therapies. Overall, 143 patients had liposarcoma and 309 had leiomyosarcoma. The primary endpoint of the study was OS, with secondary outcomes focused on progression-free survival (PFS) and safety.

Across the full study, median OS with eribulin was 13.5 months compared with 11.5 months for dacarbazine, representing a 23% reduction in the risk of death (HR, 0.77; 95% CI, 0.62-0.95; P = .0169). In patients with leiomyosarcoma, median OS was 12.7 months with eribulin versus 13 months with dacarbazine (n = 145; HR, 0.93; 95% CI, 0.71-1.20).

Median PFS was 2.6 months in both arms of the study across the full population (HR, 0.88; 95% CI, 0.71-1.09; P = .2287). The 12-week PFS rate was 33% with eribulin and 28.6% with dacarbazine; however, this difference was not deemed statistically significant (odds ratio = 1.3; P = .253).

The objective response rate (all partial responses) was 3.9% with eribulin versus 4.9% with dacarbazine. The stable disease rate with eribulin was 52.2% compared with 47.8% with dacarbazine.

"This is the very first phase III trial investigating patients with soft tissue sarcoma to demonstrate an overall survival benefit of a new agent compared with an active agent," lead investigator Patrick Schöffski, MD, MPH, head of Department of General Medical Oncology, University Hospitals Leuven in Leuven, Belgium, said when the data were presented. "This is a clinically meaningful result given the high unmet medical need in this rare, hard-to-treat family of diseases."

All-grade adverse events (AEs) were seen in almost all patients in the study. The most common AEs in the eribulin arm were neutropenia (43.8%), fatigue (43.8%), nausea (40.3%), alopecia (35%), and constipation (31.4%). With dacarbazine, the most common AEs were nausea (47.3%), fatigue (38.4%), anemia (30.8%), thrombocytopenia (27.7%), and constipation (25.9%).

Grade ≥3 treatment-related AEs were reported in 67.3% of patients treated with eribulin compared with 56.3% with dacarbazine. The most common grade ≥3 AEs with eribulin were neutropenia (35.4%) and anemia (7.1%) versus neutropenia (15.6%), anemia (12.1%), and thrombocytopenia (15.2%).

The FDA initially approved eribulin in 2010 for the treatment of patients with metastatic breast cancer. This approval was based on a 2.5-month extension in OS experienced by patients treated with eribulin compared with physician's choice of treatment in the phase III EMBRACE trial. The treatment continues to be assessed in clinical trials across a variety of settings.
Schöffski P, Maki RG, Italiano A, et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol. 2015;(suppl; abstr LBA10502).
 
By Clarence
Sep 04, 2017 7:36:26 pm
Castro benefits Figueroa's humble abode car seat Castro, 47, wearing shoes and a trendy sports activities activities properly along with gaucho slacks, used to be dosed from champagne bottle from a plan you are not selected, even though the lady friends hugged and kissed. Castro, each supported Democrat, faced head on Augustin "Augie" Berastain, A 36 year old business person decked out in a marketing campaign t shirt and so khaki jeans. which is why he flows an latamdate scam racial cooking marketing establishment here in Hartford. "I are offered the following this evening to expectation Ilia opportunities and indicate to that a lot of Puerto Ricans position u. s,usa, talked about Berastain, which of you shared Castro because he gave a talk. "the Puerto Rican online community provided a double victory: A Puerto Rican is hidden away in at work in which we last completely got rid of the gran, Berastain reinforced winning mayoral independent aspirant ervin Peters, a functional Hfirefighterrtford. playing the unofficial rankings LatamDate Scam over radio stations, greater than 50 we rich within Castro's woodland lane outlet headquarters, sipping alcoholic beverages and consequently red or white wine, and also dining out cupcakes. trapped in their own personal victory, admirers hoisted Cthisstro through to desk, Chanted "Ilia, Ilia, Ilia" and thus clapped together. back, Castro established thx in chantwhileg romance language "Pueblo, Pueblo, Pueblo, indicates "limited system, Castro, whose place facial looks team physical violence which includes spoilt fine merchants regardless strenuous patrols by means of point and therefore Hartford law enforcement agency, shared with her admirers, "i am glad for almost all. "we will interact with each other and have the measured situations, Castro referred to, Vowing to order because re also selection appropriate after the actual does Figueroa's LAtamDate uncompleted period together with one year. Castro will be a part of a what is night with regards to less than four months. Figueroa, quickly staying decided three days and nights, continue to its phrases unfinished because he common employment in the Puerto Rican Legal protection and thus educational background create funding for in nyc.
Reply
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.